Skip to main content Skip to search Skip to main navigation

Swissmedic: Amendment to GMP Compliance by Foreign Manufacturers

Swissmedic has updated its guidance on Good Manufacturing Practice (GMP) compliance for foreign manufacturers, clarifying documentation requirements for various application types (e.g., new authorizations, type IA/IB/II changes for human and veterinary medicines).

To prove GMP compliance, documents must be provided by the Responsible Person (RP). Preferably, these should be certificates from authorities with GMP systems recognized as equivalent to Switzerland’s. If such certificates are unavailable, audit reports may be accepted under specific conditions.

Key Clarifications on Audit Reports:

  • The approved audit report should be submitted with the application. Manufacturer approval depends on this report.
  • Re-audit reports with reduced scope are accepted if missing details are addressed through an RP assessment or a RP summary based on the original complete audit covering the missing points.
  • Redacted documents (report/CAPA plan) are allowed if the assessment is not compromised.
  • Audit reports must be no older than three years and must cover the relevant product.

Inspection Reports:

Reports from recognized authorities are accepted if:

  • Not older than three years,
  • The inspection was conducted on-site, 
  • Relevant to the product in question.

Veterinary Medicines:

For notifications under Art. 39 VAZV, one copy of the GMP certificate or manufacturing authorization per foreign manufacturer is sufficient. If unavailable, an RP-prepared risk assessment may be submitted instead. Swissmedic provides guidance on the required content to ensure it proves GMP compliance.

The updated guidance took effect on 1 May 2025.


Source:

Swissmedic: General communications


Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

ICH: Updated Q9(R1) Briefing Pack

ICH: Updated Q9(R1) Briefing Pack

The ICH has fully revised the Q9(R1) Briefing Pack (March/April 2026) to align with the updated ICH Q9 guideline.
Read more
EMA: New Plans for the EU GMP Guide

EMA: New Plans for the EU GMP Guide

EMA published the GMDP Inspectors Working Group’s new 2026-2028 work plan and its 2025 annual report.
Read more
EMA: Q&A on the Implementation of 3DP Technology for Solid Oral Dosage Forms

EMA: Q&A on the Implementation of 3DP Technology for Solid Oral Dosage Forms

EMA added a new GMP/Q&A section on its website and published a dedicated Q&A document on 3D printing (3DP) for solid oral dosage forms.
Read more
EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA: Pharmaceutical Quality System (PQS) Effectiveness Pilot Project

EMA launched a pilot under which EEA GMP inspectors will assess how sites demonstrate the effectiveness of their pharmaceutical quality system for risk-based change management, and whether the EEA GMP certificate could serve as the main evidence of this effectiveness.
Read more
EMA: Updated Guideline on Active Substance Chemistry

EMA: Updated Guideline on Active Substance Chemistry

The EMA has updated guidance on the information required for the manufacture and control of active substances used in medicinal products, with a 1 September 2026 date of application.
Read more
What are the Prospects and Developments in the Operation of Computerised Systems?

What are the Prospects and Developments in the Operation of Computerised Systems?

Here's the answer:
Read more
Previous
Next